DBV Technologies raises $25.5 million in Series C round

DBV Technologies SA has secured $25.5 million in a Series C round to support clinical development of a skin patch to treat peanut allergies. The round was co-led by new investors InnoBio Fund and Lundbeckfond Ventures.